

**Supplementary Table 1.** Previous studies on adjunctive lacosamide therapy in children and adolescents

Variable	Number	Age (yr)	Seizure	Epilepsy duration (yr)	No. of ASMs administered	Duration of lacosamide treatment	≥50% reduction in seizure frequency
[17] 2019 (double-blind RCT)	152 (placebo, 154)	4–7	F, DR	6.0	2–3	10 wk	52.9% (placebo, 33.3%)
[7] 2015	40	2–19	F, DR	-	7.2	10.5 mo	20%
[8] 2015	22	5.2–20.7 (mean, 12.9)	F, DR	-	7.5	11.9 mo	45%
[15] 2014 (prospective)	24	≥4 (mean, 2.7)	F, DR	-	3	At least 3 mo	42%
[5] 2014	21	1.2–17.9 (mean, 13.9)	F, DR	4.1	≥3	10.1 mo	67%
[10] 2014	79	5–15 (mean, 8.8)	F, DR	3.4	1–5	At least 3 mo	40.6%
[11] 2013	118	4–38	F, G, DR	-	1–6	6- and 12-mo follow-up	52.5% vs. 44.1%; 47.4% vs. 39%
[16] 2012 (prospective)	21	<17	F, G, DR	-	6.6	At least 3 mo	50%
[13] 2012	17	1.5–16 (mean, 8)	F, DR	5.4±3.3	6.6	9.1 mo	35%
[12] 2011	16	Mean, 14.9	F, DR	9	4.8	4 mo (1–13 mo)	37.5%
[14] 2011	18	-	F, DR	-	7	8 mo (3 wk– 17 mo)	20%

ASM, anti-seizure medication; RCT, randomized controlled trials; F, focal seizure; DR, drug-resistant seizure; G, generalized seizure.